酪氨酸激酶抑制剂对放射性碘难治性分化型甲状腺癌疗效的Meta.docx

酪氨酸激酶抑制剂对放射性碘难治性分化型甲状腺癌疗效的Meta分析

倪萃苏景阳林胜友

[关键词]?酪氨酸激酶抑制剂；放射性碘难治性分化型甲状腺癌；疗效；不良事件；Meta分析

[中图分类号]?R736.1??????[文献标识码]?A??????[DOI]?10.3969/j.issn.1673-9701.2024.01.006

Meta-analysis?of?the?efficacy?of?tyrosine?kinase?inhibitor?in?radioiodine-refractory?differentiated?thyroid?carcinoma

NI?Cui1，?SU?Jingyang2，?LIN?Shengyou3

1.Department?of?Oncology，?Hangzhou?TCM?Hospital?Affiliated?to?Zhejiang?Chinese?Medical?University，?Hangzhou?310007，?Zhejiang，?China;?2.Department?of?Oncology，?Tongde?Hospital?of?Zhejiang?Province，?Hangzhou?310012，?Zhejiang，?China;??????3.Department?of?Oncology，?the?First?Affiliated?Hospital?of?Zhejiang?Chinese?Medical?University，?Hangzhou?310003，?Zhejiang，?China

[Abstract]?Objective?To?investigate?the?effect?of?tyrosine?kinase?inhibitor?（TKI）?on?radioiodine-refractory?differentiated?thyroid?carcinoma?（RAI-rDTC）.?Methods?Literature?related?to?RAI-rDTC?was?retrieved?from?Wanfang?Data，?CNKI，?VIP，?PubMed，?Cochrane，?EmBase?and?Medline?databases?until?December?31，?2021.?Literature?quality?and?experimental?bias?were?referred?to?the?Cochrane?quality?risk?assessment?table，?and?Meta-analysis?was?performed?using?RevMan?5.3?software.?Results?A?total?of?1384?patients?were?included?in?6?studies.?The?results?of?Meta-analysis?showed?that?the?median?progress?free?survive?（HR=0.30，?95%CI：?0.18-0.50，?P0.000?01）?and?overall?survival?（HR=0.70，?95%CI：?0.57-0.88，?P=0.002）?in?treatment?group?were?significantly?longer?than?those?in?control?group.?There?was?no?significant?difference?in?complete?response?between?two?groups?（RR=3.31，?95%CI：?0.41-26.89，?P=0.26）.?The?partial?response?in?treatment?group?was?significantly?higher?than?that?in?control?group?（RR=15.97，?95%CI：?3.48-73.17，?P=0.0004）.?The?incidence?of?TKI-related?adverse?reactions?above?grade?3?in?treatment?group?was?significantly?higher?than?that?in?control?group?（RR=2.91，?95%CI：?1.70-4.96，?P0.0001）.?Conclusion?TKI?can?significantly?prolong?progress?free?survive?and?overall?survival?in?patients?with?RAI-rDTC，?but?there?